The clinical value of combined detection of CEA, NSE and CYFRA21-1 in differential diagnosis of lung cancer
- VernacularTitle:血清肿瘤标记物CEA、NSE、CYFRA21-1联合检测在肺癌鉴别诊断中的价值
- Author:
Jianxin ZUO
;
Yang LIU
;
Naikang ZHOU
- Publication Type:Journal Article
- Keywords:
lung neoplasms;
tumor markers, biological
- From:
Medical Journal of Chinese People's Liberation Army
1982;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the levels of serum CEA, NSE and CYFRA21-1 of patients with lung cancer and those with benign lung diseases, and to evaluate the clinical differential diagnostic value of combined detection of serum CEA, NSE and CYFRA21-1 in patients with lung cancer. Methods CEA, NSE and CYFRA21-1 were determined with enzyme-linked immunosorbent assay in 122 patients with lung cancer and 37 patients with benign lung diseases. The data was analyzed by t test. Results The serum levels of CEA(12.95?33.04ng/ml), CYFRA21-1(4.87?0.638ng/ml) in patients with lung cancer were significantly higher than that in those with benign lung diseases (1.92?0.84ng/ml and 4.87?0.638ng/ml, respectively)(P0.05). The levels of serum CEA, NSE and CYFRA21-1 were related to types of pathology. The highest levels of CEA, NSE and CYFRA21-1 appeared in adenocarcinoma, small cell carcinoma and squamous cell carcinoma, respectively. The level of serum of NSE (26.05?20.69ng/ml) in patients with small cell carcinoma was significantly higher than that of the patients with benign lung disease, adenocarcinoma (11.26?6.97ng/ml) and squamous cell carcinoma (12.71?7.64ng/ml), respectively (P0.05). Conclusion Combined determination of serum levels of CEA, NSE and CYFRA21-1 is helpful in differential diagnosis of lung cancers.
